Erratum: Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors (Gene Therapy (2015) 22 (840-847) Doi 10.1038/gt.2015.52);Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors

Gene Therapy

Volumn 22, Issue 10, 2015, Pages 840-847

  Trepel, M ^a,b   Korbelin J ^a   Spies, E ^a   Heckmann, M B ^c   Hunger, A ^a   Fehse, B ^a   Katus, H A ^c   Kleinschmidt, J A ^d   Muller O J ^c   Michelfelder, S ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Department of Diagnostic Radiology and Neuroradiology   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; MICRORNA; PARVOVIRUS VECTOR; SITIMAGENE CERADENOVEC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GENE THERAPY; CARDIOTOXICITY; CONTROLLED STUDY; FEMALE; GENE CASSETTE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE CANCER; NONHUMAN; PEPTIDE LIBRARY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUICIDE GENE THERAPY; SYSTEMIC THERAPY; TARGET ORGAN; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS CAPSID; ANIMAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; MAMMARY NEOPLASMS, EXPERIMENTAL; SUICIDE TRANSGENE;

ANIMALS; DEPENDOVIRUS; FEMALE; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; GENETIC VECTORS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICRORNAS;

EID: 84943455137     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.76     Document Type: Erratum

References (46)

1. Brooks JD. Translational genomics: the challenge of developing cancer biomarkers. Genome Res 2012; 22: 183-187.
2. Seth P. Vector-mediated cancer gene therapy: an overview. Cancer Biol Ther 2005; 4: 512-517.
3. Kohlschutter J, Michelfelder S, Trepel M. Novel cytotoxic vectors based on adenoassociated virus. Toxins (Basel) 2011; 2: 2754-2768.
4. Michelfelder S, Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet 2009; 67: 29-60.
5. Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Buning H et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Therapy 2003; 10: 2139-2147.
6. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008; 105: 7827-7832.
7. Maersch S, Huber A, Buning H, Hallek M, Perabo L. Optimization of stealth adenoassociated virus vectors by randomization of immunogenic epitopes. Virology 2009; 397: 167-175.
8. Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999; 5: 1052-1056.
9. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000; 74: 8635-8647.
10. Loiler SA, Conlon TJ, Song S, Tang Q, Warrington KH, Agarwal A et al. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Therapy 2003; 10: 1551-1558.
11. Kern A, Schmidt K, Leder C, Muller OJ, Wobus CE, Bettinger K et al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 2003; 77: 11072-11081.
12. White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 2004; 109: 513-519.
13. Work LM, Nicklin SA, Brain NJR, Dishart KL, Von Seggern DJ, Hallek M et al. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 2004; 9: 198-208.
14. Work LM, Buning H, Hunt E, Nicklin SA, Denby L, Britton N et al. Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther 2006; 13: 683-693.
15. White K, Buning H, Kritz A, Janicki H, McVey J, Perabo L et al. Engineering adenoassociated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Therapy 2008; 15: 443-451.
16. Michelfelder S, Kohlschutter J, Skorupa A, Pfennings S, Muller O, Kleinschmidt JA et al. Successful expansion but not complete restriction of tropism of adenoassociated virus by in vivo biopanning of random virus display peptide libraries. PLoS One 2009; 4: e5122.
17. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380: 364-366.
18. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 2002; 99: 1527-1531.
19. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004; 10: 625-632.
20. Munch RC, Janicki H, Volker I, Rasbach A, Hallek M, Buning H et al. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther 2013; 21: 109-118.
21. Wickham TJ. Ligand-directed targeting of genes to the site of disease. Nat Med 2003; 9: 135-139.
22. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and re-targeting of adeno-associated viruses. J Virol 2008; 82: 5887-5911.
23. Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C, Qiao C et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA 2009; 106: 3946-3951.
24. Ying Y, Muller OJ, Goehringer C, Leuchs B, Trepel M, Katus HA et al. Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Therapy 2010; 17: 980-990.
25. Michelfelder S, Varadi K, Raupp C, Hunger A, Korbelin J, Pahrmann C et al. Peptide ligands incorporated into the threefold spike capsid domain to redirect gene transduction of AAV8 and AAV9 in vivo. PLoS One 2011; 6: e23101.
26. Brown BD, Cantore A, Annoni A, Sergi LS, Lombardo A, Della Valle P et al. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007; 110: 4144-4152.
27. Cawood R, Chen HH, Carroll F, Bazan-Peregrino M, van Rooijen N, Seymour LW. Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog 2009; 5: e1000440.
28. Qiao C, Yuan Z, Li J, He B, Zheng H, Mayer C et al. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Therapy 2010; 18: 403-410.
29. Geisler A, Jungmann A, Kurreck J, Poller W, Katus HA, Vetter R et al. microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Therapy 2010; 18: 199-209.
30. Han C, Yu Z, Duan Z, Kan Q. Role of microRNA-1 in human cancer and its therapeutic potentials. BioMed Res Int 20142014: 428371.
31. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003; 163: 2113-2126.
32. Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ et al. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med 2011; 3: 99ra85.
33. Fend L, Accart N, Kintz J, Cochin S, Reymann C, Le Pogam F et al. Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts. PLoS One 2013; 8: e73310.
34. Hallett MA, Teng B, Hasegawa H, Schwab LP, Seagroves TN, Pourmotabbed T. Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer. Breast Cancer Res 2013; 15: R12.
35. Vandenberghe LH, Wang L, Somanathan S, Zhi Y, Figueredo J, Calcedo R et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 2006; 12: 967-971.
36. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000; 74: 1761-1766.
37. Basner-Tschakarjan E, Mingozzi F. Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front Immunol 2014; 5: 350.
38. Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 2006; 108: 3321-3328.
39. Wang Z, Storb R, Halbert CL, Banks GB, Butts TM, Finn EE et al. Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther 2012; 20: 1501-1507.
40. Hui DJ, Basner-Tschakarjan E, Chen Y, Davidson RJ, Buchlis G, Yazicioglu M et al. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol Ther 2013; 21: 1727-1737.
41. Jensen MM, Jorgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18 F-FDG-microPET or external caliper. BMC Med Imaging 2008; 8: 16.
42. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-739.
43. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC 3rd et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006; 125: 385-398.
44. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adenoassociated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
45. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973-985.
46. Rohr UP, Heyd F, Neukirchen J, Wulf MA, Queitsch I, Kroener-Lux G et al. Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles. J Virol Methods 2005; 127: 40-45.